Non-small cell lung cancer stage II
Information
- Disease name
- Non-small cell lung cancer stage II
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03383302 | Active, not recruiting | Phase 1/Phase 2 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects | February 8, 2018 | February 2026 |
| NCT04342377 | Completed | Phase 3 | The Canada Lymph Node Score Project: A Crossover Trial | November 30, 2020 | June 30, 2022 |
| NCT03550482 | Completed | Phase 4 | Oncoxin® and Quality of Life in Cancer Patients | November 1, 2017 | May 15, 2019 |
| NCT01991418 | Completed | Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) | May 2013 | February 2016 | |
| NCT05807893 | Not yet recruiting | Phase 2/Phase 3 | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases | April 14, 2023 | March 22, 2025 |
| NCT05451173 | Not yet recruiting | Phase 1/Phase 2 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | October 9, 2023 | December 31, 2025 |
| NCT06341387 | Recruiting | Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer | May 5, 2023 | July 31, 2024 | |
| NCT02622581 | Recruiting | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | December 2015 | December 2027 | |
| NCT04040361 | Recruiting | Phase 2 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | November 30, 2019 | November 30, 2025 |
| NCT04585477 | Recruiting | Phase 2 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | April 8, 2021 | April 2026 |
| NCT04716946 | Recruiting | Phase 2 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | January 27, 2021 | February 2025 |
| NCT05031533 | Recruiting | N/A | Dose-painting Radiation for LA-NSCLC | January 1, 2021 | December 2025 |
| NCT06268613 | Recruiting | Phase 1 | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | January 16, 2024 | December 2025 |
| NCT01795521 | Unknown status | Phase 2 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC | August 2015 | July 2021 |
| NCT04586465 | Unknown status | Phase 2 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC | October 10, 2020 | June 30, 2022 |